Åsmund Reikvam
Encyclopedia
Åsmund Ragnar Reikvam is a Norwegian professor in medicine and former politician.
He graduated as dr. med. in 1976 and became a specialist in Internal medicine
and Heart disease
in 1981. He worked at Ullevål university hospital
and Sogn og Fjordane central hospital, the latter as head physician in 1983–1984 and 1989–1992. In 1999 he was appointed professor in pharmacotherapeutics at the University of Oslo
.
Before moving to Oslo he was a member of Førde
municipality council for eight years, representing the Labour Party
. His brother Rolf Reikvam
is a national legislator.
Åsmund Reikvam, Professor MD, PhD, FESC, Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Norway
Åsmund Reikvam graduated from Medical School, University of Oslo, in 1970, and was a Research Fellow at the Institute of Physiology, Faculty of Medicine, University of Oslo, where he gained his PhD degree in 1976 with a thesis on “Activation and proliferation of macrophages.”
Dr. Reikvam had his main clinical training at Ullevaal University Hospital, Oslo, and became specialist in Cardiology and in Internal Medicine in 1981. After additional education at the University of Oslo in 1987 he received the Master of Health Administration degree. He has served as Chair of the Department of Medicine and Cardiology, Central Hospital of Sogn and Fjordane, and was the Medical Director of the hospital. He has been Director of Research Forum, the research organisation of Ullevaal University Hospital, Chair of the Department of Pharmacotherapeutics, University of Oslo and since 1999 Professor of Pharmacotherapeutics, now at the Institute of Clinical Medicine, University of Oslo.
He has been a member of the steering committees of important clinical trials, including the International Studies of Infarct Survival, ISIS2, ISIS3, ISIS4, and the EU funded trials of the European Secondary Prevention Study Group and, furthermore, a national co-ordinator of HOPE and GUARDIAN. He has extensive experience in clinical research. In recent years his main scientific interest has been pharmacotherapy and pharmacoepidemiology of cardiovascular diseases, particularly management of myocardial infarction. He is the author or co-author of 250 scientific papers and has published in reputable journals, including Nature, the Lancet, BMJ, Heart, Journal of Internal Medicine, European Heart Journal, European Journal of Clinical Pharmacology, and British Journal of Clinical Pharmacology.
Dr. Reikvam has served on the scientific boards of main granting agencies, including the Research Council of Norway and the Foundation for Health and Rehabilitation, chairman for ten years, and at present a member of the Board of the organisation. Until recently he has been Chair of the Norwegian Society of Pharmacoepidemiology. He is a member of The Adverse Drug Committee of the Norwegian Medical Agency.
Dr. Reikvam is a Fellow of the European Society of Cardiology (FESC) and a member of the Working Group of Cardiovascular Pharmacology and Drug Therapy of the society. He has been a member of EMEA's (European Medicines Agency) pharmacovigilance working party and has had health care evaluation assignments for OECD.
Dr. Reikvam has had leading positions within the Norwegian Medical Association (NMA), including chair of a regional department and a member of the NMA's chief decision-making body, the Representative Body. He has been active in politics and has been a member of a town council (councilor) and has also served as alderman.
He graduated as dr. med. in 1976 and became a specialist in Internal medicine
Internal medicine
Internal medicine is the medical specialty dealing with the prevention, diagnosis, and treatment of adult diseases. Physicians specializing in internal medicine are called internists. They are especially skilled in the management of patients who have undifferentiated or multi-system disease processes...
and Heart disease
Heart disease
Heart disease, cardiac disease or cardiopathy is an umbrella term for a variety of diseases affecting the heart. , it is the leading cause of death in the United States, England, Canada and Wales, accounting for 25.4% of the total deaths in the United States.-Types:-Coronary heart disease:Coronary...
in 1981. He worked at Ullevål university hospital
Ullevål University Hospital
Ullevaal, Oslo University Hospital was opened in 1887. From January 1, 2009, the hospital is part of the Oslo University Hospital.Ullevål has more than 8,600 employees. 940 of them are doctors and 2,400 nurses. With a total of 1,200 beds Ullevål, admits some 45,000 patients per year and its...
and Sogn og Fjordane central hospital, the latter as head physician in 1983–1984 and 1989–1992. In 1999 he was appointed professor in pharmacotherapeutics at the University of Oslo
University of Oslo
The University of Oslo , formerly The Royal Frederick University , is the oldest and largest university in Norway, situated in the Norwegian capital of Oslo. The university was founded in 1811 and was modelled after the recently established University of Berlin...
.
Before moving to Oslo he was a member of Førde
Førde
Førde is a municipality in the county of Sogn og Fjordane, Norway. It is located in the traditional district of Sunnfjord. The administrative center is the town of Førde which in 2010 had 12,035 inhabitants. The historic village of Bruland is located just east of the town of Førde...
municipality council for eight years, representing the Labour Party
Norwegian Labour Party
The Labour Party is a social-democratic political party in Norway. It is the senior partner in the current Norwegian government as part of the Red-Green Coalition, and its leader, Jens Stoltenberg, is the current Prime Minister of Norway....
. His brother Rolf Reikvam
Rolf Reikvam
Rolf Reikvam is a Norwegian politician for the Socialist Left Party . He was elected to the Norwegian Parliament from Akershus in 1997.He was a member of the Akershus county council from 1987-1997....
is a national legislator.
Åsmund Reikvam, Professor MD, PhD, FESC, Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Norway
Åsmund Reikvam graduated from Medical School, University of Oslo, in 1970, and was a Research Fellow at the Institute of Physiology, Faculty of Medicine, University of Oslo, where he gained his PhD degree in 1976 with a thesis on “Activation and proliferation of macrophages.”
Dr. Reikvam had his main clinical training at Ullevaal University Hospital, Oslo, and became specialist in Cardiology and in Internal Medicine in 1981. After additional education at the University of Oslo in 1987 he received the Master of Health Administration degree. He has served as Chair of the Department of Medicine and Cardiology, Central Hospital of Sogn and Fjordane, and was the Medical Director of the hospital. He has been Director of Research Forum, the research organisation of Ullevaal University Hospital, Chair of the Department of Pharmacotherapeutics, University of Oslo and since 1999 Professor of Pharmacotherapeutics, now at the Institute of Clinical Medicine, University of Oslo.
He has been a member of the steering committees of important clinical trials, including the International Studies of Infarct Survival, ISIS2, ISIS3, ISIS4, and the EU funded trials of the European Secondary Prevention Study Group and, furthermore, a national co-ordinator of HOPE and GUARDIAN. He has extensive experience in clinical research. In recent years his main scientific interest has been pharmacotherapy and pharmacoepidemiology of cardiovascular diseases, particularly management of myocardial infarction. He is the author or co-author of 250 scientific papers and has published in reputable journals, including Nature, the Lancet, BMJ, Heart, Journal of Internal Medicine, European Heart Journal, European Journal of Clinical Pharmacology, and British Journal of Clinical Pharmacology.
Dr. Reikvam has served on the scientific boards of main granting agencies, including the Research Council of Norway and the Foundation for Health and Rehabilitation, chairman for ten years, and at present a member of the Board of the organisation. Until recently he has been Chair of the Norwegian Society of Pharmacoepidemiology. He is a member of The Adverse Drug Committee of the Norwegian Medical Agency.
Dr. Reikvam is a Fellow of the European Society of Cardiology (FESC) and a member of the Working Group of Cardiovascular Pharmacology and Drug Therapy of the society. He has been a member of EMEA's (European Medicines Agency) pharmacovigilance working party and has had health care evaluation assignments for OECD.
Dr. Reikvam has had leading positions within the Norwegian Medical Association (NMA), including chair of a regional department and a member of the NMA's chief decision-making body, the Representative Body. He has been active in politics and has been a member of a town council (councilor) and has also served as alderman.